Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker, put an end to speculation about its interest in acquiring Mylan NV on Tuesday, making a $40.1 billion bid for the generics heavyweight, valuing it at $82 per share in a half cash, half stock offer.